DNLI Historical PE Ratio image   This DNLI PE ratio history page last updated 8/22/2024
DNLI Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q2 2024
8/1/2024
23.33-0.59-2.36NA
Q1 2024
5/7/2024
16.85-0.68-2.72NA
Q4 2023
2/27/2024
23.35-0.86-3.44NA
Q3 2023
11/7/2023
21.23-0.72-2.88NA
Q2 2023
8/8/2023
25.831.305.205.0
Q1 2023
5/8/2023
26.56-0.80-3.20NA
Q4 2022
2/27/2023
26.81-0.75-3.00NA
Q3 2022
11/3/2022
30.63-0.84-3.36NA
Q2 2022
8/8/2022
37.25-0.48-1.92NA
Q1 2022
5/5/2022
23.97-0.53-2.12NA
Q4 2021
2/28/2022
32.56-0.62-2.48NA
Q3 2021
11/4/2021
52.68-0.69-2.76NA
Q2 2021
8/4/2021
50.88-0.50-2.00NA
Q1 2021
5/3/2021
58.31-0.58-2.32NA
Q4 2020
2/25/2021
63.001.917.648.2
Q3 2020
11/5/2020
52.27-0.54-2.16NA
Q2 2020
8/7/2020
31.61-0.56-2.24NA
Q1 2020
5/7/2020
23.86-0.55-2.20NA
Q4 2019
2/27/2020
19.02-0.56-2.24NA
Q3 2019
11/6/2019
16.26-0.48-1.92NA
Q2 2019
8/6/2019
19.16-0.61-2.44NA
Q1 2019
5/8/2019
23.53-0.41-1.64NA
Q4 2018
3/12/2019
22.200.793.167.0
Q3 2018
11/8/2018
17.35-0.38-1.52NA
Q2 2018
8/9/2018
15.30-0.59-2.36NA
DNLI PE History Chart
PeriodPriceGAAPTTMPE
Q2 2024
8/1/2024
23.33-0.59-2.85NA
Q1 2024
5/7/2024
16.85-0.68-0.96NA
Q4 2023
2/27/2024
23.35-0.86-1.08NA
Q3 2023
11/7/2023
21.23-0.72-0.97NA
Q2 2023
8/8/2023
25.831.30-1.09NA
Q1 2023
5/8/2023
26.56-0.80-2.87NA
Q4 2022
2/27/2023
26.81-0.75-2.60NA
Q3 2022
11/3/2022
30.63-0.84-2.47NA
Q2 2022
8/8/2022
37.25-0.48-2.32NA
Q1 2022
5/5/2022
23.97-0.53-2.34NA
Q4 2021
2/28/2022
32.56-0.62-2.39NA
Q3 2021
11/4/2021
52.68-0.690.14376.3
Q2 2021
8/4/2021
50.88-0.500.29175.4
Q1 2021
5/3/2021
58.31-0.580.23253.5
Q4 2020
2/25/2021
63.001.910.26242.3
Q3 2020
11/5/2020
52.27-0.54-2.21NA
Q2 2020
8/7/2020
31.61-0.56-2.15NA
Q1 2020
5/7/2020
23.86-0.55-2.20NA
Q4 2019
2/27/2020
19.02-0.56-2.06NA
Q3 2019
11/6/2019
16.26-0.48-0.71NA
Q2 2019
8/6/2019
19.16-0.61-0.61NA
Q1 2019
5/8/2019
23.53-0.41-0.59NA
Q4 2018
3/12/2019
22.200.79NANA
Q3 2018
11/8/2018
17.35-0.38NANA
Q2 2018
8/9/2018
15.30-0.59NANA
Quotes delayed 20 minutes

Email EnvelopeFree DNLI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Denali Therapeutics (DNLI) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

DNTH PE Ratio History
DOMH PE Ratio History
DRNA PE Ratio History
DRRX PE Ratio History
DSGN PE Ratio History
DTIL PE Ratio History
DVA PE Ratio History
DVAX PE Ratio History
DXCM PE Ratio History
DYAI PE Ratio History
How should the DNLI historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Denali Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this DNLI Historical PE Ratio page.

What is the average historical PE for DNLI based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The DNLI historical PE ratio using the annualized quarterly earnings method works out to 6.7.

What is the average historical PE for DNLI based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The DNLI historical PE ratio using the TTM earnings method works out to 261.9.

On this page we presented the DNLI Historical PE Ratio information for Denali Therapeutics' stock. The average DNLI historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 6.7. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DNLI historical PE based on this TTM earnings result method is 261.9. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DNLI historical PE result, against the recent PE: when this page was posted on 8/21/2024, the most recent closing price for DNLI had been 25.00, and the most recent quarterly earnings result, annualized, was 5.2. Meanwhile, the most recent TTM earnings summed to 0.14. From these numbers, we calculate the recent DNLI PE on 8/21/2024 based on annualized quarterly EPS was 4.8. Based on DNLI's history, that recent PE is low relative to the historical average, with the recent PE 28.4% lower than the historical average PE across our data set for Denali Therapeutics. Looking at the recent DNLI PE on 8/21/2024 based on TTM EPS, we calculate the ratio at 178.6. Based on DNLI's history, that recent PE is low relative to the historical average, with the recent PE 31.8% lower than the average PE across our Denali Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on DNLI or any other given stock, valuation analysis for DNLI can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Denali Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DNLI. Thanks for visiting, and the next time you need to research DNLI Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: Funds Holding NJR, NIC YTD Return, YAC Options Chain.

 

DNLI Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.